Skip to main content

Table 5 Economic impact (mean total cost) of comorbidities, divided by the number of comorbidities

From: Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice

  HIV+ mono-infected patients HIV/HCV co-infected patients Delta between HIV/HCV and HIV+ patients [%] p-value between HIV/HCV and HIV+ patients
No comorbidity € 8,272.18 € 12,897.43
€ 10,382.67a
35.86%
25.51%a
< 0.001
< 0.001a
One comorbidity € 9,566.95 € 17,426.32
€ 11,159.68a
82.15%
14.27%a
< 0.001
0.001a
Two comorbidities € 11,423.22 € 18,348.50
€ 11,896.95a
37.74%
3.98%a
0.018
> 0.050a
Three or more comorbidities € 12,532.49 € 12,755.15
€ 12,228.53a
1.75%
− 2.49%a
> 0.050
> 0.050a
One way ANOVA 0.095 0.0554   
  1. aAverage cost without considering costs incurred for HCV therapy